<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4273316/" ref="ordinalpos=574&amp;ncbi_uid=6989566&amp;link_uid=PMC4273316" image-link="/pmc/articles/PMC4273316/figure/Fig6/" class="imagepopup">Figure 6.  From: Exogenous IFN-beta regulates the RANKL-c-Fos-IFN-beta <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> in the collagen antibody-induced arthritis model. </a></div><br /><div class="p4l_captionBody"> <b>Changes in the RANKL-RANK signaling pathway after exogenous IFN-β treatment in the CAIA model mice.</b> The levels of RANKL <b>(A)</b>, TRAF6 <b>(B)</b>, c-Fos <b>(C),</b> and NFATc-1 <b>(D)</b> in the joints of mice in the IFN-β intervention and non-intervention groups. *: P &lt;0.05.</div></div>